Thursday 13 August 2020 ,
Latest News
15 July, 2020 12:15:22 PM / LAST MODIFIED: 15 July, 2020 02:46:55 PM

Print

Experimental Covid-19 vaccine trial generating immune response

Independent Online/ Xinhua
Experimental Covid-19 vaccine trial generating immune response

mRNA-1273, an experimental COVID-19 vaccine, was generally well tolerated and prompted neutralising antibody activity in healthy adults, according to interim results published in The New England Journal of Medicine online on Tuesday.

The ongoing phase 1 trial is supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The experimental vaccine, co-developed by researchers at NIAID and U.S.

biotech company Moderna, is designed to induce neutralizing antibodies directed at a portion of the coronavirus "spike" protein, which the virus uses to bind to and enter human cells.

The trial, led by Lisa Jackson of Kaiser Permanente Washington Health Research Institute in Seattle, was launched on March 16 when the first participant received the candidate vaccine.

The interim report detailed the initial findings from the first 45 participants aged 18-55 enrolled at the study sites in Seattle and at Emory University in Atlanta.

Three groups of 15 participants received two intramuscular injections, 28 days apart, of either 25, 100, or 250 micrograms of the investigational vaccine.

In April, the trial was expanded to enroll adults aged above 55, and it now has 120 participants.

No serious adverse events were reported, according to the study. More than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site. Systemic adverse events were more common following the second vaccination and in those who received the highest vaccine dose.

The interim analysis includes results of tests measuring levels of vaccine-induced neutralizing activity through day 43 after the second injection.

Two doses of the vaccine prompted high levels of neutralizing antibody activity that was above the average values seen in convalescent sera obtained from persons with confirmed COVID-19 disease, according to the study.

A Phase 2 clinical trial of mRNA-1273, sponsored by Moderna, began enrollment in late May.

Moderna plans to begin its final phase of testing for the vaccine on July 27.

TH

 

 

Comments

Poll
Today's Question »
State minister for power Nasrul Hamid yesterday said everyone to have access to electricity by June. Do you think the feat achievable by the timeframe?
 Yes
 No
 No Comment
Yes 47.3%
No 48.7%
No Comment 4.1%
Video

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting